Press Releases Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
34.54 ^USD	-0.12%		+9.06%	+55.10%

02/05	Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss	MT
02/05	Transcript : Agios Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024	04:30pm	AQ
Agios Pharmaceuticals : First Quarter 2024 Financial Results Presentation	02/05	PU
Agios Pharmaceuticals: Q1 Earnings Snapshot	02/05	AQ
Agios Reports Business Highlights and First Quarter 2024 Financial Results	02/05	AQ
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024	18/04	AQ
Agios Publishes 2024 Environmental, Social and Governance Report	10/04	AQ
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report	09/04	AQ
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024	06/03	AQ
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024	05/03	AQ
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024	22/02	AQ
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	15/02	AQ
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024	02/02	AQ
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio	08/01	AQ
Agios Pharmaceuticals : ENERGIZE Phase 3 Topline Results	03/01	PU
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia	03/01	AQ
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024	02/01	AQ
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition	10/12	AQ
One-Year Safety and Efficacy of Mitapivat in Sickle Cell Disease: Follow-Up Results of a Phase 2, Open-Label Study	10/12	PU
A Patient-Centric Approach to Sickle Cell Disease Clinical Trials: Integrating Patient Perspectives in the RISE UP Phase 2/3 Trial of Mitapivat for Informed Protocol Design and Associated Patient Community Benefit	09/12	PU
Long-term Safety and Efficacy of Mitapivat, an Oral Pyruvate Kinase Activator, in Adults with Sickle Cell Disease: Extension of a Phase 1 Dose Escalation Study	09/12	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Agios Pharmaceuticals, Inc.

Equities

AGIO

US00847X1046

Press Releases

Filters